Femasys Inc
NASDAQ:FEMY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Femasys Inc
Pre-Tax Income
Femasys Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Femasys Inc
NASDAQ:FEMY
|
Pre-Tax Income
-$18.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Pre-Tax Income
$3.7B
|
CAGR 3-Years
38%
|
CAGR 5-Years
76%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Pre-Tax Income
$1.3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Stryker Corp
NYSE:SYK
|
Pre-Tax Income
$4.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Pre-Tax Income
$8.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Pre-Tax Income
$3.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
22%
|
CAGR 10-Years
16%
|
|
Femasys Inc
Glance View
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.
See Also
What is Femasys Inc's Pre-Tax Income?
Pre-Tax Income
-18.6m
USD
Based on the financial report for Dec 31, 2025, Femasys Inc's Pre-Tax Income amounts to -18.6m USD.
What is Femasys Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-22%
Over the last year, the Pre-Tax Income growth was 1%. The average annual Pre-Tax Income growth rates for Femasys Inc have been -18% over the past three years , -22% over the past five years .
